Outcomes of Six-Dose High-Dose Cytarabine as a Salvage Regimen for Patients with Relapsed/Refractory Acute Myeloid Leukemia.

We present a retrospective review of 26 consecutive patients with RR-AML receiving single agent cytarabine 3 g/m(2) intravenously every 12 hours on days 1, 3, and 5 for a total of six doses (HiDAC-6). Median follow-up for surviving patients was 10.4 months (range 1.6-112.2 months). Complete remission was obtained in 62% (54% CR and 8% CRi) of the patients. The median relapse-free survival (RFS) was 22.3 months (range 0.7-112 months), event-free survival (EFS) was 4.7 months (range 0.5-112 months), and the overall survival (OS) was 9.6 months (range 1-112 months). Thirty-five percent of patients were able to subsequently proceed to allo-HCT. Treatment-related toxicities included neutropenic fever (38%), infection (35%), neurotoxicity (8%), and skin toxicity (8%). This is the first study to demonstrate HiDAC-6 as an active treatment option for younger patients with RR-AML which can effectively serve as a bridge to allo-HCT without significant toxicity. PMID: 28588617 [PubMed]
Source: Advances in Hematology - Category: Hematology Tags: Adv Hematol Source Type: research